MiMedx Group (MDXG) delivered the operating repair it promised but not the growth to go with it. The company reported an adjusted loss of $0.01 per share for the third quarter, down 106.7% from the prior year, on revenue of $62.28 million, down 45.2%. On a GAAP basis, MiMedx lost $0.06 per share versus a $0.11 profit a year ago. Those comparisons were expected after January's Medicare reimbursement changes gutted the Wound franchise. The real news is the mix of good and bad below the headline. Cost cuts restored positive adjusted EBITDA and pushed gross margin back to 80%. At the same time, management cut full-year revenue guidance again, Surgical growth slowed, and the Sanara MedTech acquisition ran into an FTC delay. That is the central tension: the cost base has been fixed, but the top line has not stabilized.

The margin story deserves credit. GAAP gross margin rose to 80% from 69% in the second quarter, still below the 84% of a year ago. That beat the low-70s full-year framing management offered on its first-quarter call, and the company expects gross margin to hold near 80% in the fourth quarter. Adjusted EBITDA came in at $2.1 million, a 3.3% margin and roughly a $10 million sequential improvement, though far below the $35.0 million (30.7% margin) of a year ago. The quality of the quarter is mixed, however. SG&A of $58 million included about $6 million of incremental legal and Sanara transaction costs. Operating cash flow of $3.9 million also benefited from a sharply lower receivables balance. The balance sheet is a genuine strength: MiMedx repaid its remaining $17 million term loan and ended the quarter debt-free with $121 million in cash, up $2 million sequentially.

The revenue picture is where bears have legitimate ammunition. Full-year sales guidance is now $250 million to $260 million. That is down from $260 million to $290 million on the first-quarter call and far below the $340 million to $360 million outlook from February. Management described the quarter as roughly flat sequentially. Surgical sales grew 9% to $40.0 million, or about 12% excluding a tough tissue comparison and rebate true-ups. That still marks a steady slowdown from 25% in the fourth quarter of 2025, then 13% and 15% in the first two quarters of this year, and the fourth quarter is guided to high single digits. Management pointed to mid-teens unit volume growth, softer industry procedure volumes, and promotional rebates as explanations. Wound sales fell 71% to $22.3 million, essentially unchanged from the first quarter. Management conceded the recovery is proceeding more slowly than anticipated and now expects 2027 wound market conditions to resemble 2026. That is a notable retreat from earlier talk of double-digit growth in both franchises next year. The arithmetic is also unforgiving on profitability: nine-month adjusted EBITDA stands at a $17.6 million loss. With the fourth quarter guided only sequentially higher, the first-quarter goal of full-year breakeven appears out of reach.

There were real offsetting positives. Wound Care Center unit volume rose 7% sequentially and more than 20% year over year, an early sign that patients are migrating to settings where MiMedx is positioned well. The company signed a $25 million patent license, payable in five $5 million annual installments, with two larger patent cases still pending. A federal court vacated the FDA's classification of AXIOFILL and sent the matter back to the agency. Management also expects at least one 510(k) clearance for new surgical products before year-end. Against those positives, the FTC's second request has pushed the Sanara close, originally targeted for October, out with no timeline. Meanwhile, a ticking fee accrues on the $300 million Hayfin financing commitment. Management reiterated its long-term targets of low double-digit sales growth and an adjusted EBITDA margin above 20%.

Investor sentiment improved meaningfully heading into the report, rising from -0.35 to -0.04. That is a shift from clearly negative to roughly neutral, not a turn to optimism. Price action has been less forgiving. At $3.90, shares were unchanged from the open after the July report and sat 9.5% below the 200-day moving average of $4.31. The stock had given back most of a September run to $4.99 and traded just 6.3% above its October 22 low of $3.67. Trend readings are mixed, with improving momentum alongside negative price and AVWAP trends. The market had already stripped out the late-summer optimism before this guidance cut arrived.

The bottom line is that MiMedx proved it can run a leaner, higher-margin, Surgical-led business with a clean balance sheet and growing IP monetization. It did not prove the top line has found a floor. Repeated guidance cuts, decelerating Surgical growth, a Wound reset now expected to stretch through 2027, and an open-ended Sanara delay leave the recovery story dependent on execution that has yet to show up in revenue.